Molecular and Cellular Pediatrics is a leading journal published by SPRINGERNATURE, dedicated to advancing knowledge in the fields of pediatrics, perinatology, and child health through innovative molecular and cellular research. Since its transition to Open Access in 2014, the journal has facilitated widespread dissemination of critical findings, making it accessible to a global audience of researchers, healthcare professionals, and students. The journal's scope encompasses a range of topics that explore the intersection of molecular biology and pediatric medicine, aiming to bridge gaps in our understanding of child health and development. With Scopus rankings placing it at the 48th percentile in pediatrics and a significant focus on cutting-edge research, Molecular and Cellular Pediatrics plays an essential role in shaping future research and clinical practices in the field. Its commitment to academic rigor and accessibility makes it a vital resource for those dedicated to improving pediatric health outcomes.

CURRENT MOLECULAR MEDICINE is a pivotal journal fostering advancements in the interdisciplinary fields of molecular medicine, biochemistry, and genetics. Published by Bentham Science Publishers, this esteemed journal has been disseminating vital research findings since its inception in 2001 and is continuously dedicated to exploring the molecular basis of health and disease. With a focus on translational research, CURRENT MOLECULAR MEDICINE provides an invaluable platform for researchers, healthcare professionals, and students, making significant contributions to the understanding of molecular mechanisms and therapeutic strategies. With an ISSN of 1566-5240 and an E-ISSN of 1875-5666, the journal holds a commendable position within the scientific community, being ranked Q3 in Biochemistry and Molecular Biology and Q2 in Medicine (miscellaneous) as of 2023. This journal does not currently operate on an open access model but remains accessible through various institutional subscriptions. The multidisciplinary scope covering molecular biology to medicinal applications positions CURRENT MOLECULAR MEDICINE as an essential resource for those striving to meet the challenges of modern healthcare and biomedical research.

HUMAN IMMUNOLOGY, published by Elsevier Science Inc, serves as a critical platform for disseminating research in the fields of immunology and allergy, as well as various aspects of miscellaneous medicine since its inception in 1980. With an ISSN of 0198-8859 and E-ISSN 1879-1166, this journal is pivotal for researchers and practitioners looking to advance their understanding of human immune responses and related conditions. The journal currently holds a respectable position within its field, as highlighted by its 2023 Scopus ranks—#114/233 in Immunology and Allergy and #132/236 in Immunology and Microbiology. Moreover, it maintains a Q2 quartile ranking in both Immunology and Allergy and miscellaneous Medicine, underscoring its influence and reach within the scientific community. Although it does not currently offer Open Access options, HUMAN IMMUNOLOGY remains dedicated to providing valuable insights and fostering academic discourse within its discipline, characterized by a rigorous peer-review process and a focus on innovative research trajectories.

GENE THERAPY, published by SpringerNature, is a prestigious academic journal at the forefront of research in the fields of genetics, molecular biology, and molecular medicine. Since its inception in 1994, this journal has evolved into a vital resource for scholars, practitioners, and students, providing cutting-edge insights into gene therapy techniques and innovations. With an impressive impact factor reflecting its significant influence— ranking in the Q1 quartile across multiple categories in 2023—GENE THERAPY offers rigorous peer-reviewed articles that address both basic and applied aspects of gene therapy. The journal is recognized for its role in promoting advancements in therapeutic strategies, thus enhancing understanding of genetic disorders and treatment efficacy. Researchers will find this journal invaluable for publishing their findings, staying updated on the latest breakthroughs, and fostering interdisciplinary collaborations. Engage with the latest in gene therapy by accessing this influential platform, and contribute to a field that holds the potential to transform healthcare outcomes worldwide.

Molecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.

International Journal of Molecular and Cellular Medicine, published by the CELLULAR & MOLECULAR BIOLOGY RESEARCH CENTER in Iran, is a leading platform dedicated to advancing research in various domains of molecular and cellular sciences. With an ISSN of 2251-9637 and E-ISSN 2251-9645, this journal features a rigorous peer-review process that ensures the publication of high-quality, impactful research. Spanning from 2016 to 2024, it is categorized in the third quartile (Q3) in Biochemistry, Cell Biology, Genetics, and Molecular Biology, and second quartile (Q2) in Biotechnology, underlining its significance in the scientific community. Although currently non-open access, it maintains credible visibility through Scopus rankings, reflecting its importance in fields such as Biochemistry, Molecular Medicine, and Genetics, where it holds respectable ranks and percentiles. This journal aims to foster collaboration and knowledge dissemination among researchers, professionals, and students in the pursuit of enhancing understanding and innovation in molecular and cellular medicine.

Current Molecular Pharmacology, published by Bentham Science Publishers, is a prominent journal focused on the dynamic fields of pharmacology, drug discovery, and molecular medicine. With an ISSN of 1874-4672 and an E-ISSN of 1874-4702, this journal aims to disseminate cutting-edge research and review articles that showcase innovative methodologies and groundbreaking findings from 2008 through 2024. Holding a respectable Q3 category ranking in Drug Discovery, Molecular Medicine, and Pharmacology for 2023, Current Molecular Pharmacology serves as an essential platform for both established researchers and emerging scholars to share their insights. The journal is indexed in Scopus with its relevant ranks catering to pharmacology and molecular biology, ensuring it reaches a wide array of professionals, researchers, and students in the field. As a contributor to advancing pharmacological sciences, this journal provides invaluable access to the latest advancements and fosters ongoing dialogue in molecular pharmacology, positioning itself as a key resource in the exploration of therapeutic agents and their interactions.

Cold Spring Harbor Perspectives in Medicine is a premier academic journal published by the esteemed COLD SPRING HARBOR LAB PRESS that has become a crucial resource in the fields of Biochemistry, Genetics, and Medicine. With an impressive impact factor and consistently ranked in the Q1 quartile for both biochemistry and general medicine—as evidenced by its Scopus rankings of #21 and #26 respectively—this journal serves as an essential platform for disseminating high-quality research and comprehensive reviews from leading experts. Covering a convergence of knowledge spanning from 2011 through 2024, it plays a vital role in advancing the understanding of medical science. Researchers, professionals, and students alike benefit from Cold Spring Harbor Perspectives in Medicine, which offers a depth of insight into critical topics, emerging trends, and essential developments within the medical community. Join the conversation and contribute to the ongoing dialogue that drives innovation and excellence in medical research.

Journal of Biomedical Research, published by Nanjing Medical University in China, is a prominent platform for groundbreaking discoveries in the fields of Biochemistry, Genetics, and Molecular Biology, as well as Medicine. With an ISSN of 1674-8301 and an E-ISSN of 1876-4819, the journal offers a vital opportunity for researchers, professionals, and students to disseminate insightful research findings. Although not currently available as an open access journal, its inclusion in the second quartile of both Biochemistry and Medicine categories underscores its growing influence and commitment to high-quality scholarship, as evidenced by its historical compliance with Scopus rankings prior to 2009. By fostering an interdisciplinary approach, the Journal of Biomedical Research aims to bridge gaps in current biomedical understanding and encourages innovative research that can lead to significant contributions in improving health outcomes. Its editorial policies guarantee rigorous peer review, making it a trusted source of knowledge in the biomedical community.

Aging-US is a premier peer-reviewed journal dedicated to advancing the field of aging research and cell biology. Published by IMPACT JOURNALS LLC, this journal serves as a vital resource for researchers and professionals exploring the biological mechanisms of aging and their implications for health and disease. With a commendable impact factor reflected in its 2023 Scopus rankings, where it stands at Rank #10/38 in the category of Aging and Rank #63/285 in Cell Biology, Aging-US exemplifies rigorous scientific excellence. Its open access policy enhances accessibility, fostering a wider dissemination of knowledge in both academic and clinical settings. Spanning from 2009 to 2024, the journal provides a platform for groundbreaking studies and innovative methodologies, ensuring that it remains at the forefront of the dynamic conversations surrounding aging and cellular biology. Engage with Aging-US to contribute to the evolving narratives of longevity and cellular health.